1. Home
  2. |Professionals
  3. |Anne Elise Herold Li

Anne Elise Herold Li

Partner
Partner
YWxpQGNyb3dlbGwuY29t
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Anne is co-chair of the firm’s Life Sciences and Patents groups. She is a first-chair trial lawyer in intellectual property who focuses on biotech, pharma, life sciences, and medical device industries. She has successfully represented clients using outside-the-box strategies, both in and out of the courtroom. Her goal is always to reach a good business resolution, but when that is not possible, she zealously uses litigation as a tool to get the best outcome for her clients. She represents clients whose groundbreaking products and services raise complex legal questions at the nexus of collaborators and competitors, including those times when one shifts to the other. She has successfully represented companies in bet-the-company litigations, often scoring key wins long before trial, resulting in favorable settlements.

Companies rely on Anne to help them navigate the intersection of intellectual property and business because she provides in-house counsel with patent, unfair competition, and trade secret advice that is practical and actionable. She takes time to learn a client’s business—from biotech startups to multibillion-dollar pharmaceutical companies and everything in between—so she can help them develop bespoke strategies that work for their unique situations.

Clients also appreciate Anne’s ability to match legal strategies with their risk tolerance and business objectives. Her approach is informed by her commitment to developing long-standing relationships with in-house counsel and her knowledge of the industry and related technologies.

Furthering Anne’s commitment to creating a strong and wide-reaching network across industries and the bar, Anne serves on the Executive Committee of the William C. Conner Inn of Court and is active in the NY Intellectual Property Law Association. She is also a member of Crowell’s Pro Bono Committee.

Career & Education

|

    • University of Chicago, B.A., psychology
    • Emory University, M.P.H.
    • Fordham University School of Law, J.D.
    • University of Chicago, B.A., psychology
    • Emory University, M.P.H.
    • Fordham University School of Law, J.D.

    • District of Columbia
    • New York
    • Supreme Court of the United States
    • U.S. Court of Appeals for the Federal Circuit
    • U.S. District Court for the Southern District of New York
    • U.S. District Court for the Eastern District of New York
    • U.S. District Court for the District of Columbia
    • U.S. Patent and Trademark Office (USPTO)
    • District of Columbia
    • New York
    • Supreme Court of the United States
    • U.S. Court of Appeals for the Federal Circuit
    • U.S. District Court for the Southern District of New York
    • U.S. District Court for the Eastern District of New York
    • U.S. District Court for the District of Columbia
    • U.S. Patent and Trademark Office (USPTO)

  • Professional Activities and Memberships

    • Vice-Chair, Medical Devices, ABA Science & Technology Law Section, 2017 – 2018
    • New York Intellectual Property Law Association 
    • Executive Committee, William C. Conner Inn of Court

    Professional Activities and Memberships

    • Vice-Chair, Medical Devices, ABA Science & Technology Law Section, 2017 – 2018
    • New York Intellectual Property Law Association 
    • Executive Committee, William C. Conner Inn of Court

Anne's Insights

Firm News | 1 min read | 11.08.24

Crowell & Moring Represents Marshall Wace as Lead Investor in Inquis Medical’s $40 Million Series B Financing

San Francisco – November 8, 2024:  Marshall Wace led Inquis Medical’s oversubscribed $40 million Series B round, along with participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond.

View All Insights

Representative Matters

  • Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.
  • Successfully defended Agilent against a preliminary injunction filed by Waters Corp. by demonstrating that Waters was unlikely to succeed on the merits. The case ultimately settled.
  • Successfully represented a large pharmaceutical company in a false advertising and unfair competition case.

Anne's Insights

Firm News | 1 min read | 11.08.24

Crowell & Moring Represents Marshall Wace as Lead Investor in Inquis Medical’s $40 Million Series B Financing

San Francisco – November 8, 2024:  Marshall Wace led Inquis Medical’s oversubscribed $40 million Series B round, along with participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond.

View All Insights

Recognition

  • The National Law Journal: Emerging Therapies/Life Sciences Trailblazer, 2023
  •  IAM Patent 1000: Recommended – United States: National, Trade Secret Litigation, 2023
  • Law360: Burton Award, Distinguished Legal Writing, 2023
  • Chambers USA: Intellectual Property: Patent (Up and Coming) – New York, 2022-2023

Anne's Insights

Firm News | 1 min read | 11.08.24

Crowell & Moring Represents Marshall Wace as Lead Investor in Inquis Medical’s $40 Million Series B Financing

San Francisco – November 8, 2024:  Marshall Wace led Inquis Medical’s oversubscribed $40 million Series B round, along with participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond.

View All Insights

Insights

Firm News | 1 min read | 11.08.24

Crowell & Moring Represents Marshall Wace as Lead Investor in Inquis Medical’s $40 Million Series B Financing

Client Alert | 6 min read | 10.23.24

Unfinished Business in Congress on Drug Patents and Competition

Client Alert | 3 min read | 10.15.24

Can False Claims of Patent Protection Land You in the False Advertising Dawg(s) House?

Client Alert | 3 min read | 07.22.24

USPTO Offers Updated Guidance on Patent Subject Matter Eligibility for AI
|

View All Insights